Day: June 11, 2020

In a release issued under the same headline on Thursday, June 11th by Focus Graphite Inc. (TSX-V: FMS; OTCQX: FCSMF; FSE: FKC), the fifth paragraph has been omitted and the information redacted. The corrected release follows:KINGSTON, Ontario, June 11, 2020 (GLOBE NEWSWIRE) — Focus Graphite Inc. (“Focus” or the “Company”) (TSX-V: FMS; OTCQX: FCSMF; FSE: FKC), an advanced exploration company focused on the production of graphite concentrate announced today that the Board of Directors has adopted a new 20% fixed incentive stock option plan (the “New Plan”) to replace the previous rolling stock option plan (the “Old Plan”). The Company also announced the grant of incentive stock options under the New Plan as compensation to its directors, officers, employees and consultants (the “New Grant”).Pursuant to the...

 KIRKLAND, Wash., June 11, 2020 (GLOBE NEWSWIRE) — Monolithic Power Systems (MPS) (Nasdaq: MPWR), a leading company in high performance analog solutions, today announced the final results of the 2020 Annual Meeting of Stockholders held on June 11, 2020 (the “Annual Meeting”). Stockholders re-elected the two director nominees with 73% and 59% of the votes cast for their election, ratified the appointment of MPS’s independent registered public accounting firm for 2020 with 100% of the votes cast for ratification, approved the 2019 compensation of executive officers with 98% of the votes cast for approval, and approved the amendment and restatement of the Amended Monolithic Power Systems, Inc. 2014 Equity Incentive Plan with 70% of the votes cast for approval.“On behalf of the Board and management, I sincerely thank our stockholders...

SANTA CLARA, Calif., June 11, 2020 (GLOBE NEWSWIRE) — SiTime Corporation (Nasdaq: SITM), a market leader in MEMS timing, announced today the pricing of its follow-on public offering of 3,500,000 shares of its common stock at a price to the public of $32.00 per share, including 2,500,000 shares of common stock to be sold by MegaChips Corporation and 1,000,000 shares of common stock to be issued and sold by SiTime. SiTime will not receive any proceeds from the sale of shares of common stock by MegaChips Corporation. The gross proceeds of the offering to SiTime, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $32,000,000, excluding any exercise of the underwriters’ option. Net proceeds to SiTime are expected to be used for repayment of debt and general corporate purposes. The...

GOODYEAR, Ariz., June 11, 2020 (GLOBE NEWSWIRE) — LGI Homes, Inc. (Nasdaq:LGIH) announced Terrata Homes is now selling brand-new luxury homes in Segovia at Estrella™ by Newland Communities. This is Terrata’s second section of meticulously designed move-in ready homes within this amenity-rich community.At Segovia, Terrata Homes has unveiled a brand-new collection of one-story single family homes. These five newly designed floor plans range in size from 2,112 square feet to 2,777 square feet. With up to five bedrooms and three baths, these new homes are designed with the needs of the customer in mind. Open floor plans, centrally located family rooms, private master suites, spacious walk-in closets, game rooms, private offices, formal dining rooms, outdoor living spaces and professionally landscaped front yards are just a sampling...

Preclinical results demonstrated leronlimab effectively inhibited fatty liver developmentVANCOUVER, Washington, June 11, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today initiation of the Company’s Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).  The Phase 2 trial is designed to test whether leronlimab may control the devastating liver fibrosis associated with NASH. As previously reported, the Company’s preclinical study demonstrated strong positive data highlighting the potential of leronlimab in treating nonalcoholic fatty liver disease (NAFLD), a common precursor to nonalcoholic steatohepatitis (NASH)....

CALGARY, Alberta, June 11, 2020 (GLOBE NEWSWIRE) — Tornado Global Hydrovacs Ltd. (“Tornado” or the “Company”) (TGH: TSX-V) today reported its audited consolidated financial results for the fiscal year ended December 31, 2019. The audited consolidated financial statements and MD&A have been filed on SEDAR and can be reviewed at www.sedar.com and on the Company’s web site www.tornadotrucks.com.Financial and Operating Highlights (in CAD $000’s except per share data)1 Earnings (loss) before interest, tax, depreciation, amortization, impairment write-down and stock-based compensation (“EBITDAS”) and earnings (loss) before interest and tax (“EBIT”) are not defined by IFRS. The definition of EBITDAS does not consider gains and losses on the disposal of assets, fair value changes in foreign currency forward contracts and non-cash components...

VANCOUVER, British Columbia, June 11, 2020 (GLOBE NEWSWIRE) — Reservoir Capital Corp. (CSE: REO) (“REO” or the “Company”) announces that it will likely miss its filing deadline of June 15, 2020 to file annual consolidated financial statements and accompanying management’s discussion and analysis and related CEO and CFO certificates for the financial period ended December 31, 2019 (collectively, the “Annual Filings”), as required under applicable Canadian securities laws.In connection with the Company’s inability to file the Annual Filings on time, the Company has applied for a Management Cease Trade Order (“MCTO”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”) and is waiting for British Columbia Securities Commission approval.The Company is applying for a MCTO as a result of complexities caused by COVID-19...

CALGARY, Alberta, June 11, 2020 (GLOBE NEWSWIRE) — Parkland Corporation (“Parkland”) (TSX:PKI) announces that a dividend of $0.1012 per share will be paid on July 15, 2020 to shareholders of record on June 22, 2020. The dividend will be an ‘eligible dividend’ for Canadian income tax purposes. The ex-dividend date is June 19, 2020.Enhanced Dividend Reinvestment PlanParkland’s enhanced Dividend Reinvestment Plan (“Enhanced DRIP”) allows shareholders to reinvest their cash dividends to purchase additional Parkland shares from treasury at a 5% per share discount to the average of the daily volume weighted average trading prices during the Pricing Period. For further details on the Enhanced DRIP and the Pricing Period, please visit www.parkland.ca/en/investors/dividend/.Shareholders who wish to enroll in...

HOUSTON, June 11, 2020 (GLOBE NEWSWIRE) — Bristow Group Inc. (NYSE:VTOL) and Era Group Inc. (“Era”) announced today that they have completed their combination (the “Merger”), creating a financially stronger company with enhanced size and diversification. The newly combined company will use the Bristow Group name (“Bristow”) and will remain a publicly traded company on the New York Stock Exchange.  The newly combined company’s common stock will begin trading under the stock ticker “VTOL” beginning on June 12, 2020 and will have a new CUSIP number of 11040G103.  “The closing of this strategic and financially compelling merger makes Bristow a larger, more diverse and stronger company, better positioned for the future,” said Chris Bradshaw, President and CEO of Bristow. “The combination brings long-overdue consolidation in the industry,...

GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) — Viela Bio (Nasdaq:VIE) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNATM (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive as a twice-a-year maintenance regimen following initial doses. Approximately 80%1 of all patients with NMOSD test positive for anti-AQP4 antibodies.“NMOSD is an extremely challenging disease to treat. Patients experience unpredictable attacks that can lead to permanent disability from blindness and paralysis. In addition, each subsequent attack may result in a cumulative worsening of disability. In the pivotal N-MOmentum trial, UPLIZNATM—a humanized CD19-directed monoclonal antibody—significantly reduced the risk of attacks and...